GlassScriptPhysician profile
Cynthia Antonio
NPI 1962745554
$6,769.50
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,905 · 2022: $2,204 · 2023: $2,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,440.83 | 2021-2023 | Mounjaro, Jardiance, Trulicity |
| Mannkind Corporation | $706.74 | 2021-2023 | Afrezza |
| Novo Nordisk INC | $645.86 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $395.96 | 2021-2023 | Repatha, Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $362.92 | 2021-2023 | Farxiga |
| Embecta Corp. | $242.17 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Abbvie INC. | $242.15 | 2021-2023 | |
| Abbott Laboratories | $231.35 | 2021-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $215.08 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.53 | 2021-2023 | Jardiance |
| Bigfoot Biomedical INC | $209.66 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $203.05 | 2022-2023 | |
| Cequr Corporation | $171.67 | 2022-2023 | Cequr Simplicity |
| Radius Health, INC. | $157.93 | 2021-2023 | Tymlos |
| Horizon Therapeutics Plc | $142.49 | 2023 | Tepezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $114.14 | 2021-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $103.88 | 2021-2023 | |
| Pfizer INC. | $101.60 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $98.52 | 2021-2023 | Steglatro |
| Zealand Pharma US, INC. | $94.10 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $91.97 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $76.09 | 2023 | |
| Corcept Therapeutics | $72.67 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $70.18 | 2021-2023 | Gvoke Hypopen |
| Insulet Corporation | $68.20 | 2023 | Omnipod |
| Alexion Pharmaceuticals, INC. | $62.07 | 2023 | Strensiq |
| Ibsa Pharma INC. | $56.18 | 2021-2023 | Tirosint, Licart |
| Becton, Dickinson and Company | $40.15 | 2022 | |
| Medtronic, INC. | $35.95 | 2021-2022 | |
| Amryt Pharma Holdings LTD | $35.31 | 2022 | |
| Currax Pharmaceuticals LLC | $26.83 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $22.09 | 2021 | |
| Halozyme INC | $19.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Antonio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.